Respiratory viral infections such as influenza and COVID-19 have been linked to the awakening of dormant breast cancer cells, potentially hastening metastatic progression and elevating mortality risks among cancer survivors, as per recent research findings. Breast cancer, a prevalent malignancy globally, often leads to death due to metastatic disease that emerges after prolonged periods of clinical dormancy. To delve into the influence of respiratory infections on this process, scientists conducted experiments with mice and analyzed extensive human datasets. In mouse models, researchers observed how influenza and SARS-CoV-2 infections disrupted the dormancy of disseminated cancer cells in the lungs. Concurrently, they analyzed cancer survivor data from the UK Biobank and Flatiron Health databases, which included cohorts of all cancers and breast cancer-specific populations.
The outcomes from animal models indicated that both influenza and SARS-CoV-2 infections prompted dormant breast cancer cells in the lungs to transition to a proliferative state within days, resulting in a substantial 100-fold expansion into metastatic lesions within a mere 2 weeks. This shift was primarily instigated by IL-6-induced inflammation and sustained through immune modulation, where CD4+ T cells hindered the activation and cytotoxicity of CD8+ T cells. Notably, the presence of HER2+ tumors further intensified this immunosuppressive environment. In tandem with these experimental discoveries, analyses of human cohorts revealed that SARS-CoV-2 infection notably heightened cancer-related mortality and the risk of metastatic lung disease in survivors, with the risk peaking in the immediate months post-infection, aligning with the temporal dynamics observed in the mouse models.
This study underscores the potent impact of viral infections in disrupting tumor dormancy, thereby fostering metastatic relapse in susceptible populations. The authors suggest that existing therapies, such as IL-6 receptor antagonists and JAK1/2 inhibitors already used for severe COVID-19 cases, may present promising avenues to curb infection-driven cancer progression, although their efficacy would need clinical affirmation. The critical need for strategies to mitigate infection-related risks in cancer, especially in the face of emerging and seasonal respiratory pathogens, is emphasized by these findings.
The research signifies a crucial step towards understanding how cell state modulation, induced by respiratory viral infections, can potentially influence the progression of breast cancer towards metastasis. By elucidating the molecular mechanisms underlying this phenomenon, the study opens up avenues for targeted interventions that could mitigate the impact of infections on cancer outcomes. As the medical community grapples with the dual challenge of managing viral infections like influenza and COVID-19 alongside cancer progression, the insights from this study could inform the development of novel therapeutic strategies aimed at safeguarding cancer survivors from infection-induced metastatic relapse.
- Understanding the interplay between respiratory viral infections and breast cancer progression offers insights into potential therapeutic strategies.
- The study highlights the need for precision medicine approaches to address the unique vulnerabilities of cancer survivors to infection-induced metastatic relapse.
- Harnessing existing therapies approved for severe COVID-19 cases may hold promise in mitigating infection-driven cancer progression.
- Strategies to mitigate infection-related risks in cancer patients are crucial, particularly in the context of emerging and seasonal respiratory pathogens.
Read more on emjreviews.com